Pluri Inc is a biotechnology company, that creates cell-based products for commercial use and is pioneering a biotech revolution that promotes wellbeing and sustainability. The company’s technology platform developed a three-dimensional, or 3D, technology platform for cell expansion with an industrial scale in-house Good Manufacturing Practice, or GMP, cell manufacturing facility. It uses its technology in the field of regenerative medicine, food tech and agricultural technology or agtech.
2001
118
LTM Revenue n/a
LTM EBITDA n/a
$35.2M
Benchmark forward-looking revenue and EBITDA valuation multiples across generative AI, climate tech, semiconductors, online marketplaces, vertical SaaS and 220 more verticals.
Pluri has a last 12-month revenue of n/a and a last 12-month EBITDA of n/a.
In the most recent fiscal year, Pluri achieved revenue of $0.3M and an EBITDA of -$20.2M.
Pluri expects next 12-month revenue of XXX   and NTM EBITDA of XXX
See Pluri valuation multiples based on analyst estimatesFY 2023 | FY 2024 | FY 2025 | LTM | NTM | |
---|---|---|---|---|---|
Revenue | $0.3M | $0.3M | XXX | XXX | XXX |
Gross Profit | n/a | $0.3M | XXX | XXX | XXX |
Gross Margin | NaN% | 85% | XXX | XXX | XXX |
EBITDA | -$27.7M | -$20.2M | XXX | XXX | XXX |
EBITDA Margin | -9645% | -6204% | XXX | XXX | XXX |
Net Profit | -$41.2M | -$28.3M | XXX | XXX | XXX |
Net Margin | -14370% | -8687% | XXX | XXX | XXX |
Net Debt | $11.9M | $18.2M | XXX | XXX | XXX |
Financial data powered by Morningstar, Inc.
As of April 15, 2025, Pluri's stock price is $4.
Pluri has current market cap of $27.3M, and EV of $35.2M.
See Pluri trading valuation dataEV | Market Cap | Price 1D | Price 1M | Price 3M | Price 12M | EPS |
---|---|---|---|---|---|---|
$35.2M | $27.3M | XXX | XXX | XXX | XXX | n/a |
Sign up to access valuation multiples like growth-adjusted P/E, next 12-month EV/Revenue, EBITDA multiples by industry and many more
Sign UpAs of April 15, 2025, Pluri has market cap of $27.3M and EV of $35.2M.
Pluri's trades at n/a LTM EV/Revenue multiple, and n/a LTM EBITDA.
Analysts estimate Pluri's 2025E EV/Revenue multiple at XXX and 2025E EV/EBITDA multiple at XXX
See valuation multiples for Pluri and 10K+ public compsFY 2024 | FY 2025E | FY 2026E | FY 2027E | |
---|---|---|---|---|
EV | $35.2M | XXX | XXX | XXX |
EV/Revenue | 32.7x | XXX | XXX | XXX |
EV/EBITDA | n/a | XXX | XXX | XXX |
P/E | -1.2x | XXX | XXX | XXX |
P/E/Growth | n/a | XXX | XXX | XXX |
EV/FCF | n/a | XXX | XXX | XXX |
Valuation data powered by FactSet, Inc. and Morningstar, Inc.
Access all public comps and forward-looking valuation multiples like EV/Revenue in 2025, based on equity research analyst estimates.
Sign UpPluri's NTM/LTM revenue growth is Infinity%
Pluri's revenue per employee for the last fiscal year averaged $3K, while opex per employee averaged $0.2M for the same period.
Over next 12 months, Pluri's ratio of sales and marketing spend to revenue is estimated to be XXX , while its R&D spend to revenue to be XXX .
Analysts estimate Pluri's 2025E EV/Revenue multiple at XXX and 2025E EV/EBITDA multiple at XXX
See operational valuation multiples for Pluri and other 10K+ public compsFY 2024 | NTM | FY 2025E | FY 2026E | FY 2027E | |
---|---|---|---|---|---|
Revenue Growth | 14% | XXX | XXX | XXX | XXX |
EBITDA Margin | n/a | XXX | XXX | XXX | XXX |
EBITDA Growth | -27% | XXX | XXX | XXX | XXX |
Rule of 40 (SaaS-only) | n/a | XXX | XXX | XXX | XXX |
Revenue per Employee | $3K | XXX | XXX | XXX | XXX |
Opex per Employee | $0.2M | XXX | XXX | XXX | XXX |
S&M Expenses to Revenue | n/a | XXX | XXX | XXX | XXX |
G&A Expenses to Revenue | 3078% | XXX | XXX | XXX | XXX |
R&D Expenses to Revenue | 3818% | XXX | XXX | XXX | XXX |
Opex to Revenue | 6896% | XXX | XXX | XXX | XXX |
Valuation data powered by FactSet, Inc. and Morningstar, Inc.
Benchmark public comps and private revenue and EBITDA valuation multiples across GRC software, cloud infrastructure, DevOps, online marketplaces and so much more!
EV/Revenue | EV/EBITDA | |||||
---|---|---|---|---|---|---|
2025E | 2026E | 2027E | 2025E | 2026E | 2027E | |
Lineage Cell Therapeutics | XXX | XXX | XXX | XXX | XXX | XXX |
Arovella Therapeutics | XXX | XXX | XXX | XXX | XXX | XXX |
Aroa Biosurgery | XXX | XXX | XXX | XXX | XXX | XXX |
Cynata Therapeutics | XXX | XXX | XXX | XXX | XXX | XXX |
Mesoblast | XXX | XXX | XXX | XXX | XXX | XXX |
XXXXXXXX | XXX | XXX | XXX | XXX | XXX | XXX |
XXXXXXXX | XXX | XXX | XXX | XXX | XXX | XXX |
Valuation data powered by FactSet, Inc.
Pluri acquired XXX companies to date.
Last acquisition by Pluri was XXXXXXXX, XXXXX XXXXX XXXXXX . Pluri acquired XXXXXXXX for XXX (EV/Revenue multiple of XXX ).
See M&A valuation multiplesAcquired Company | EV | EV/Revenue | EV/EBITDA |
---|---|---|---|
XXXXXXXXX | XXX | XXX | XXX |
XXXXXXXXX | XXX | XXX | XXX |
XXXXXXXXX | XXX | XXX | XXX |
XXXXXXXXX | XXX | XXX | XXX |
XXXXXXXXX | XXX | XXX | XXX |
Sign up to see revenue and EBITDA valuation multiples for 60K+ M&A deals.
Sign UpWhen was Pluri founded? | Pluri was founded in 2001. |
Where is Pluri headquartered? | Pluri is headquartered in United States of America. |
How many employees does Pluri have? | As of today, Pluri has 118 employees. |
Who is the CEO of Pluri? | Pluri's CEO is Mr. Yaky Yanay. |
Is Pluri publicy listed? | Yes, Pluri is a public company listed on NAS. |
What is the stock symbol of Pluri? | Pluri trades under PLUR ticker. |
When did Pluri go public? | Pluri went public in 1991. |
Who are competitors of Pluri? | Similar companies to Pluri include e.g. Lineage Cell Therapeutics, Arovella Therapeutics, Aroa Biosurgery, Cynata Therapeutics. |
What is the current market cap of Pluri? | Pluri's current market cap is $27.3M |
What is the current revenue growth of Pluri? | Pluri revenue growth between 2023 and 2024 was 14%. |
Is Pluri profitable? | Yes, Pluri is EBITDA-positive (as of the last 12 months). |
Get access to always up-to-date, precisely categorized 70K+ public and private valuation multiples, across tech and beyond.